Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts

Kuros Biosurgery AG

Overview

This is a randomised, controlled, open-label study of a single intralesional administration of I-040302 or a single bone marrow aspirate or a single steroid injection (methylprednisolone). Subjects will undergo screening with X-ray and magnetic resonance imaging (MRI) in the diagnosis of a solitary bone cyst.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Bone Cysts

Interventions

I-040302DRUG

doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34

Standard of CareOTHER

Bone marrow aspirate or steroids

Eligibility

Sex: ALLMin age: 6 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects 6 - 16 years of age 2. Diagnostic evidence of unicameral bone cysts based on one or more of a combination of any of the following methods: * Cyst fluid examination * Plain radiographs * MRI 3. Subjects with the following types of cysts: * Intact cysts that are either growing or at risk of fracture, requiring surgical intervention * Persistence of a cyst cavity following cyst fracture that has received conservative treatment/s to repair the fracture * Persistence of a cyst cavity despite repeated interventions 4. Subjects with bone cyst volumes \< 30 mL 5. Subjects must be appropriately communicative to verbalise pain. 6. Subjects must be able to understand and be willing to comply with the protocol procedures. 7. Subjects who have provided written informed consent to participate in the study 8. The legally authorised representative of the child must give written informed consent after the child has agreed to participate in the study. Exclusion Criteria: 1. A history of/or presence of active cancer 2. Family history of retinoblastoma 3. Indication of aneurysmal bone cyst on MRI, cyst aspiration or histology 4. Possible presence of osteosarcoma or uncertain histology 5. Systemic or localised infection at time of surgery 6. Evidence of immune-suppression 7. Evidence of hypercalcemia 8. Cyst volume \> 30 mL 9. Fracture present in the cortical bone surrounding the cyst 10. Evidence of rapid venous drainage from the cyst determined by rapid disappearance of X-ray contrast medium during the surgical process. 11. Suspected or known evidence of allergic reactions towards any of the components of I-040302 12. Known clinically significant organ or systemic diseases such that, in the opinion of the investigator, the significance of the disease will compromise the subject's participation in the study 13. Pregnant or lactating females 14. Participation in another clinical trial within 3 months prior to trial start